Compass Pathways (NASDAQ:CMPS), a company developing psychedelic pharmaceutical drugs for the mental health space, announced the publication of two new investigator-initiated studies using its flagship compound, COMP360.
COMP360 is a synthetic isolate of psilocybin, the active compound commonly found in psilocybe mushrooms, also known as “magic mushrooms.” The molecule is currently moving to phase 3 clinical trials, after closing phase 2 in November of last year. Compass is expecting to have COMP360 approved by the FDA.
